ProQR Therapeutics « Terug naar discussie overzicht

ProQR Therapeutics 2019

2.656 Posts, Pagina: « 1 2 3 4 5 6 ... 62 63 64 65 66 67 68 69 70 71 72 ... 129 130 131 132 133 » | Laatste

Omlaag ↓

[verwijderd] 13 juli 2019 05:22

Tom.. I wrote few things that are so important to why the price of Proqr went up and may go up even much more and much faster. but needs one to "hear"

Tom3 13 juli 2019 10:48

quote:
joel12 schreef op 13 juli 2019 05:22:
Tom.. I wrote few things that are so important to why the price of Proqr went up and may go up even much more and much faster. but needs one to "hear"

Thanks for the reminder. That is why I have invested decent amounts of money in ProQR, Arrowhead and AFMD. Their science could be game changers. Strong management is a bonus. In the end Big Pharma must be willing to buy these companies. Only very few will escape and emerge as runner-up big pharma. Arrowhead fits in this picture. ProQR too if they show improvement is some areas. AFMD is my wild card.

[verwijderd] 13 juli 2019 11:38

you take a stab at Proqr almost at every corner Tom.
Proqr has done in the shortest time what Arwr and definetly AFMD have not in their wildest dreams.

Afmd is a 20+ years long company with currently 1 clinical candidate. during the 20 years has scraped out at least 5 candidates.

Arwr also has been around for a long time and may have a chance ,, though who knows? its technology is not highly differentiated from alny, drna, abus
but in the past months Gilead said it will buy out an RNAi company and its valuation went up . has also a multi million dollar partnership so its more "safe"

anyway. the idea is that there is only one Proqr. and it does majic. dont mix it with substitutes.

Tom3 13 juli 2019 12:17

www.pharmasalmanac.com/articles/what-...

De Boer lijkt het Axiomer platform naar voren te gaan schuiven:

Daniel A. de Boer,
Chief Executive Officer, ProQR Therapeutics N.V.
A: One truly novel technology that could have significant impact on the lives of patients in the future is the use of RNA editing. Targeted RNA editing has the potential to directly correct the causes of genetic conditions. While therapies are still in the early stages of development, RNA editing potentially combines the benefits of both gene therapy and small molecule therapies. Like gene therapy and gene editing, RNA editing can specifically repair a disease-causing gene mutation but can do so without permanently changing a person's genetic code, reducing the chance of permanent off-target effects. Additionally, like small molecule drugs and unlike gene-editing therapies, small molecule RNA-editing therapies can often be administered in simple fashion and delivered without viral vectors. There are thousands of diseases caused by genetic mutations that can be corrected with RNA editing, and we have only just begun to witness the impact these types of therapies can have on the lives of people suffering from devastating genetic conditions.

Tom3 13 juli 2019 12:43

quote:
joel12 schreef op 13 juli 2019 11:38:
you take a stab at Proqr almost at every corner Tom.
Proqr has done in the shortest time what Arwr and definetly AFMD have not in their wildest dreams.

Afmd is a 20+ years long company with currently 1 clinical candidate. during the 20 years has scraped out at least 5 candidates.

Arwr also has been around for a long time and may have a chance ,, though who knows? its technology is not highly differentiated from alny, drna, abus
but in the past months Gilead said it will buy out an RNAi company and its valuation went up . has also a multi million dollar partnership so its more "safe"

anyway. the idea is that there is only one Proqr. and it does majic. dont mix it with substitutes.

You forgot this one:
ir.arrowheadpharma.com/static-files/5...

AFMD has closed a significant partnership with Genentech/Roche.

ProQR still has no partner. Do you think this will change soon?

[verwijderd] 13 juli 2019 14:40

i dont forget anything.
ARWR first of all failed its first main trial and now hopes to do better with a combination.. y know that?
arwr has a similar maybe identical technology as DRNA and ABUS which last has 1/10 or less valuation.

yes ARWR and AFMD did partnerships so what? AGTC had a 1 bill dollar partnership that felt apart ,,, the examples of companies to had done billion dollars partnerships and ultimately go down in flames is loooooooong.
OMED .. oncomed.. read about it.. billion dollars partnerships with Celgene.. done. zero.

the AFMD partnership may or may not seek value for the company. dont know .. if it will it will take years to see that. i think best for t company to get bought out.

in any case in most cases the upside of the companies is before the partnerships are done not after. case in point AFMD went up from 1.5 to 7. in the past FATE went p from 1 to 8 or so when Juno did partnership w it.. and went down and then took a long time to go back up again.

if you ask weather proqr will do a partnership? hhhhhh no it will never do ... :)

Tom3 13 juli 2019 18:42

ABUS went from $11 to $ 2,40 in one year so I doubt they have identical technology compared to ARWR (that went from $ 16.40 to $ 27.15 in one year). ProQR went from $ 23 (March 2015) to $ 3 (March 2018) due to successes? But may be it is now time to invest in ABUS.

4finance 13 juli 2019 19:03

quote:
Tom3 schreef op 13 juli 2019 18:42:
ABUS went from $11 to $ 2,40 in one year so I doubt they have identical technology compared to ARWR (that went from $ 16.40 to $ 27.15 in one year). ProQR went from $ 23 (March 2015) to $ 3 (March 2018) due to successes? But may be it is now time to invest in ABUS.

Dat ABUS heb ik ook al eens naar gekeken. Is dat een gokje waard?

[verwijderd] 13 juli 2019 19:33

ARWR also had the same descent what in the world are you talking about? finviz.com/quote.ashx?t=ARWR&ty=c...

and stop taking stabs at Proqr because that doesnt make you any smarter.

as to that one company went up while the other went down .. that doesnt immediately say about their respective technologies being the same or not. biotech investing is more complicated than going to the supermarket and judging based on price which product is better.

[verwijderd] 13 juli 2019 23:30

En nu maandag zakken?

Tom3 14 juli 2019 00:34

quote:
4finance schreef op 13 juli 2019 19:03:
[...]

Dat ABUS heb ik ook al eens naar gekeken. Is dat een gokje waard?

AB 729 is hun nieuwe troefkaart na teleurstellende resultaten van ARB 1467. Ik heb geen idee of dat gaat werken:

www.evaluate.com/vantage/articles/new...

Blackrock zit er nog in met een flinke portie aandelen, wellicht is het toch niet zo slecht als de meesten op de beurs nu denken.

Tom3 14 juli 2019 00:49

quote:
De Troon Jan schreef op 13 juli 2019 23:30:
En nu maandag zakken?

Hoezo? Nabeurs was er nog een levendige handel waar tot $ 9,50 per aandeel werd betaald. Ik heb echter geen hoera verhalen op social media etc gezien tot nu toe. We moeten het maar afwachten.

[verwijderd] 14 juli 2019 02:22

Oké laten we hopen dat we dit vast houden en daarna omhoog

[verwijderd] 14 juli 2019 05:43

There is a big chance that the biotech index XBI will start the week down. thats because technically, altough ready to breakout, its against resistance and looks a bit weak at least for the next day or so.

If the buys in Proqr where in expectation of some meaningful news from the weekends conference .. and nothing , which most likely thats the case, will come out,, Monday the stock will go down as those that bought, maybe day traders will sell .

however , there are many possible other scenarios .. and could be that Proqr not only will not go down, but rather explode on news that should be in the area of business development.

so
1) if the jump was due to day traders or swing traders expecting news from the weekend .. it will go down Monday.
2) but if the buys where insiders knowing what will happen outside of the weekends presentation.. it will go up and continue based on the magnitude of the upcoming news.

i am ready for both scenarios. hope however the 2) will happen.

Hunter300 14 juli 2019 08:18

July 12, 2019 08:35 AM EDT
R&D
Broad star Feng Zhang unveils a new CRISPR platform, editing RNA and eliminating Alzheimer's threat — in cells
Broad Institute star scientist Feng Zhang is back in the spotlight, adapting CRISPR technology in a shift from permanently editing DNA to revising RNA — temporarily if needed. And he illustrated the promise of this approach by deactivating APOE4, which may be a ticking time bomb for people at risk of developing Alzheimer’s.

CRISPR/Cas9 gene editing tech has taken the lab by storm, in part because of the work Zhang and his one-time colleagues Jennifer Doudna and Emmanuelle Charpentier accomplished. They’re still scrapping over the patents to the original Cas9 work. But Zhang, who founded Beam Therapeutics with David Liu and Keith Joung, has moved on in search of better tech, and in a paper published in Science, says they have made real progress in switching from DNA to RNA editing.

They call this new advance RESCUE: RNA Editing for Specific C to U Exchange. And it builds on REPAIR: RNA Editing for Programmable A to I.

Using Cas13, Zhang’s team was able to take the APOE4 gene — believed to carry the added risk of spurring Alzheimer’s — and changed it to a benign APOE2. The RNA editors converted “the nucleotide base adenine to inosine, or letters A to I. Zhang and colleagues took the REPAIR fusion and evolved it in the lab until it could change cytosine to uridine, or C to U.”

But there are also ways to achieve a temporary change that could benefit patients without creating potential risks.

In a separate cell experiment, Zhang and his group were able to orchestrate a transitory spike in ß-catenin activation and cell growth. That kind of temporary impact could erase threats of cancer, associated with uncontrolled cell growth while treating wounds.

“To treat the diversity of genetic changes that cause disease, we need an array of precise technologies to choose from. By developing this new enzyme and combining it with the programmability and precision of CRISPR, we were able to fill a critical gap in the toolbox,” says Zhang, the James and Patricia Poitras Professor of Neuroscience at MIT.

It’s an intriguing experiment, but don’t look for the experiment in cells to make the leap into practice anytime soon. MIT’s Jonathan Gootenberg summed it up for WBUR:

“It’s a first step in a very large journey. We’re still at the base of the mountain, you might say.”

AUTHOR

This article was posted on Twitter a few days ago by John Carroll (Endpoints news). I think it shows that even the DNA editing guru’s see a huge potential in RNA editing.

holenbeer 14 juli 2019 09:22

Tja, dan kan je voor de zekerheid maar beter wat spreiden in recent afgestrafte RNA-clubs, lijken mensen te hebben gedacht.

[verwijderd] 14 juli 2019 10:00

right on! it also says clearly that in the brain better to modify the RNA and not the DNA

to add to that the words of Proqr CEO here www.pharmasalmanac.com/articles/what-...

are relevant and important.

[verwijderd] 14 juli 2019 20:52

big congrats to probably the worlds best biotech company GLPG for the todays gilead upsized partnership. i just wonder if todays proqr buys where not due to that.. and how it will work out between the 2 neighbors

[verwijderd] 14 juli 2019 21:31

thanx...after ProQR my biggest investment...exciting day tommorrow!

J@@p11 14 juli 2019 21:41

Vrijdag tegen € 128,- alles verkocht. Shit Happens.

2.656 Posts, Pagina: « 1 2 3 4 5 6 ... 62 63 64 65 66 67 68 69 70 71 72 ... 129 130 131 132 133 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	15 mei 2024 22:00
Koers	1,910
Verschil	-0,075 (-3,78%)
Hoog	1,990
Laag	1,880
Volume	120.844
Volume gemiddeld	171.821
Volume gisteren	249.624

ProQR Therapeutics 2019

Meedoen aan de discussie?

Direct naar Forum

Detail

ProQR Therapeutics NV nieuws meer